Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) Director Michael Thomas Heffernan sold 39,473 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total value of $595,647.57. Following the completion of the transaction, the director owned 6,351 shares in the company, valued at $95,836.59. The trade was a 86.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Trevi Therapeutics Trading Up 1.5%
Shares of TRVI stock traded up $0.22 during trading on Thursday, hitting $15.23. The company’s stock had a trading volume of 1,498,737 shares, compared to its average volume of 1,702,766. The company has a market cap of $2.17 billion, a PE ratio of -44.79 and a beta of 1.04. The business has a fifty day moving average of $17.60 and a 200-day moving average of $15.30. Trevi Therapeutics, Inc. has a 52 week low of $8.03 and a 52 week high of $20.22.
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, research analysts predict that Trevi Therapeutics, Inc. will post -0.48 EPS for the current year.
Analyst Ratings Changes
View Our Latest Research Report on Trevi Therapeutics
Institutional Investors Weigh In On Trevi Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV bought a new position in Trevi Therapeutics during the first quarter worth about $29,000. Hilton Head Capital Partners LLC purchased a new stake in shares of Trevi Therapeutics during the 4th quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Trevi Therapeutics during the 4th quarter valued at approximately $50,000. Avidity Partners Management LP purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at approximately $79,000. Finally, Seven Fleet Capital Management LP bought a new position in Trevi Therapeutics in the 4th quarter worth approximately $89,000. 95.76% of the stock is currently owned by institutional investors.
About Trevi Therapeutics
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors.
Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes.
Featured Articles
- Five stocks we like better than Trevi Therapeutics
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
